Skip to content

Neogen NEOG Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
$18.16M+152%
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$211.2M-4.4%
Gross profit$99.0M-10.2%
Operating income-$3.3M-161%
Net income-$17.0M-56.0%
EPS (diluted)-$0.08-60.0%

Balance sheet

See full
Cash & equivalents$159.9M+25.2%
Total debt$793.3M-11.2%
Total equity$2.1B-21.0%
Total assets$3.4B-16.8%

Cash flow

See full
Operating cash flow$22.7M+16.7%
CapEx$11.6M-64.7%
Free cash flow$11.1M+182%

Valuation

See full
Market cap$1.96B+95.6%
Enterprise value$2.59B+46.1%
P/S2.3×+1.1×

Profitability

See full
Gross margin45.2%-3.6pp
Operating margin-73.1%+77.7pp
Net margin-69.9%+30.8pp
FCF margin-14%

Returns & leverage

See full
Return on equity-25.6%+28.8pp
Debt / equity0.4×0.0×
Current ratio3.9×0.0×

Where this comes from

Reported directly by Neogen in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Neogen’s 10-Q, filed April 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neogen's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neogen's proceeds from exercises of stock options and other stock issuances?
Neogen (NEOG) reported proceeds from exercises of stock options and other stock issuances of $822K in Q4 2025.
How has Neogen's proceeds from exercises of stock options and other stock issuances changed year-over-year?
Neogen's proceeds from exercises of stock options and other stock issuances decreased by 19.3% year-over-year, from $1.02M to $822K.
What is the long-term trend for Neogen's proceeds from exercises of stock options and other stock issuances?
Over 2 years (2023 to 2025), Neogen's proceeds from exercises of stock options and other stock issuances has grown at a 37.0% compound annual growth rate (CAGR), from $1.2M to $2.24M.